SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy is trending amid mixed sentiments as traders discuss recent price volatility and potential catalysts. Some community members express frustration with price action and question the project's long-term viability, while others remain optimistic about Propy's role in real-world asset tokenization and anticipate future growth.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as the community discusses its recent price action, potential bottom, and upcoming earnings report. Call options activity and LEAPS are being highlighted, while some traders debate the stock's valuation and potential for a run-up. Additionally, some analysts are weighing in with price target adjustments.

ARK Investment Management LLC - ARK Innovation ETF

ARK Innovation ETF

ARKK is trending as investors assess its recent performance and potential for future growth amid discussions around innovation and disruptive technologies. The ETF's holdings, including TSLA, and potential investment strategies are key talking points. Community members are weighing the fund's long-term outlook and debating whether it represents a trading or investment opportunity.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending amidst discussions about its valuation, Medicare Advantage plans, and potential partnerships, particularly with Clover Health. The stock's volatile price action and perceived manipulation are also key talking points among investors. Some analysts suggest the recent pullback is an overreaction and highlight the company's long-term potential and attractive entry points.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is experiencing increased interest, mirroring the recent surge in other privacy coins like ZEC, with community members speculating if it will follow a similar trajectory.  Discussions revolve around its potential for significant gains, its relatively low supply, and possible integrations with payment platforms. Some traders are noting bullish chart patterns and anticipating a substantial price increase.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as interoperability, staking rewards, real-time processing, and an improved overall extensibility, which is hard to achieve in a completely trustless manner using only Nakamoto consensus.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrade routines, allowing for more rapid, iterative development

eCash

eCash is trending as the community discusses the upcoming Avalanche Pre-Consensus upgrade, promising instant finality and faster transactions. Content from the Electronic Cash Conference (ECC) 2025 is also driving interest, with talks covering scalability, scripting, and the network's vision for peer-to-peer electronic cash. Community members are highlighting staking opportunities and new ecosystem tools.

Tidal Trust II - Defiance Daily Target 2X Long HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

Defiance Daily Target 2X Long HIMS ETF ($HIMZ) is trending as traders discuss potential bounce plays and rebounds, with some expressing bullish sentiment. Community members are actively analyzing technical indicators and potential support levels for entry points, while also weighing the impact of $HIMS earnings and JPMorgan Chase's increased ownership. Some traders are discussing using $HIMZ to play swings and capitalize on the volatility of $HIMS.

BlackRock Institutional Trust Company N.A. - iShares Russell 1000 Growth ETF

iShares Russell 1000 Growth ETF

IWF is trending amid discussions about growth versus value stocks and potential rotations in market leadership. Options activity suggests some investors anticipate continued upside, while others are hedging against potential declines. Community members are analyzing technical indicators and ETF flows to gauge the strength and direction of the Russell 1000 Growth ETF.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson ($JNJ) is trending due to positive Q3 earnings and future sales guidance, along with plans to spin off its Orthopaedics unit. The community is focused on call options, strength in key drugs and MedTech, and strategic repositioning. Talc-related legal challenges and potential acquisitions are also being actively discussed.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending as investors discuss its potential role in powering AI data centers, particularly given its partnership with ExxonMobil and technology for carbon capture. The community highlights the company's advantageous position with natural gas-based fuel cells amid increasing AI energy demands. Some are drawing comparisons to Bloom Energy's success and anticipating significant upside for FCEL.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a clinical master supply agreement with Swiss healthcare company Roche (RHHBY) for hard-to-treat cancer therapies.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply">agreement</a> aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.Checkpoint inhibitors are a type of immunotherapy used to treat cancer. They work by blocking proteins called checkpoints that cancer cells use to evade the immune system.MAIA CEO Vlad Vitoc said that Ateganosine was found to be “highly synergistic and effective” in combination with Roche’s Atezolizumab in preclinical studies.MAIA’s Ateganosine is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.Ateganosine is presently being developed as a second or later line of treatment for NSCLC for patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.On Stocktwits, retail sentiment around MAIA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed unchanged at ‘low’ levels.<figure class="image"><img style="aspect-ratio:630/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_10_02_21_AM_png_d32286ea58.webp" alt="MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits" width="630" height="66"><figcaption>MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the new agreement.<stembedurl>https://stocktwits.com/MoneyHelix/message/618266998</stembedurl>Another opined that it's “not bad news.”<stembedurl>https://stocktwits.com/share97/message/618262353</stembedurl><a href="https://stocktwits.com/symbol/MAIA">MAIA stock </a>is down by 11% this year and by over 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/air-india-boeing-crash-emergency-power-system-may-have-deployed-mid-flight/chls3JTRR2d">Air India Boeing Crash: Report Says Emergency Power System May Have Deployed Mid-Flight, Raising Engine Failure Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Equity

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.


This account has been verified as an official MAIA representative.

Verified Account

MAIA Biotechnology

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

MAIA Biotechnology Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MAIA
MAIA Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAIA News

MAIAMAIA Biotechnology Inc